Home > Boards > US OTC > Medical - Healthcare > InVivo Therapeutics Holdings Corp (NVIV)

Where did the $16 million go?

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
XenaLives Member Profile
Member Level 
Followed By 333
Posts 44,696
Boards Moderated 26
Alias Born 09/20/01
160x600 placeholder
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 10/23/2020 4:39:28 PM
InVivo Therapeutics Announces Pricing of $15.0 Million Public Offering Business Wire - 10/22/2020 9:15:00 AM
Securities Registration Statement (s-1) Edgar (US Regulatory) - 10/7/2020 6:01:32 AM
InVivo Therapeutics Announces Presentation at the Upcoming H.C Wainwright Virtual Global Investment Conference Business Wire - 9/11/2020 8:30:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/11/2020 4:15:47 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/5/2020 4:34:29 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/23/2020 6:37:34 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 6/22/2020 6:04:21 AM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 6/9/2020 4:31:40 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/5/2020 4:06:18 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 6/5/2020 6:01:40 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 6/4/2020 4:35:19 PM
Securities Registration Statement (s-1) Edgar (US Regulatory) - 5/22/2020 5:26:10 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/13/2020 4:07:21 PM
Small Company Offering and Sale of Securities Without Registration (d) Edgar (US Regulatory) - 4/28/2020 4:15:49 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 4/24/2020 5:05:10 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 4/24/2020 4:15:10 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 4/24/2020 11:19:24 AM
InVivo Therapeutics Announces Closing of $3.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules Business Wire - 4/17/2020 12:19:00 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 4/17/2020 6:01:44 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/16/2020 5:20:33 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 4/16/2020 11:30:13 AM
InVivo Therapeutics Announces $3.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules Business Wire - 4/15/2020 7:30:00 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 3/16/2020 4:45:23 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/12/2020 7:02:36 PM
XenaLives Member Level  Friday, 01/17/20 07:10:33 AM
Re: XenaLives post# 6131
Post # of 6165 
Where did the $16 million go?

Why the need to raise $840K


CAMBRIDGE, Mass. (November 22, 2019) – InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) today announced the closing of its previously announced public offering of 7,000,000 shares of its common stock, par value $0.00001 per share, at a price to the public of $0.12 per share. The gross proceeds from this offering are $840,000, before deducting the fees and estimated offering expenses payable by InVivo Therapeutics. The offering closed on November 22, 2019.

H.C. Wainwright & Co. acted as exclusive placement agent for the offering.

A registration statement on Form S-3 (File No. 333-234353) relating to the shares of common stock offered in the offering was filed with the Securities and Exchange Commission, or the SEC, and was declared effective by the SEC on November 14, 2019. The offering was made only by means of a prospectus supplement and accompanying base prospectus, which are part of the effective registration statement. A final prospectus supplement related to the offering was filed with the SEC and is available on the SEC’s website at www.sec.gov. Electronic copies of the final prospectus supplement and accompanying base prospectus may also be obtained by contacting H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York, New York 10022, via e-mail at placements@hcwco.com or via telephone at (646) 975-6996.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.



https://www.invivotherapeutics.com/press-releases/invivo-therapeutics-announces-closing-of-public-offering-of-common-stock/


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences